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Energy metabolismCancer cells are resistant to apoptosis and show a shift in energy production from mitochondrial oxidative
phosphorylation to cytosolic glycolysis. Apoptosis resistance andmetabolic reprogramming are linked inmany
cancer cells and both processes center on mitochondria. Clearly, mutated cancer cells escape surveillance and
turn into selﬁsh cells. However, many of the mechanisms that operate cellular metabolic control still function
in cancer cells. This review describes the metabolic importance of glucose and glutamine, glycolytic enzymes,
oxygen, growth cofactors and mitochondria and focuses on the potential role of bioactive food components,
including micronutrients. The role of B- and A-vitamin cofactors in (mitochondrial) metabolism is highlighted
and the cancer protective potential of omega-3 fatty acids and several polyphenols is discussed in relation to
metabolic reprogramming, including the mechanisms that may be involved. Furthermore, it is shown that
cancer cell growth reduction by limiting the growth cofactor folic acid seems to be associated with reversal of
metabolic reprogramming. Altogether, reversal of metabolic reprogramming may be an attractive strategy to
increase susceptibility to apoptotic surveillance. Food bioactive components that affect various aspects of
metabolism may be important tools to reverse glycolytic to oxidative metabolism and enhance sensitivity to
apoptosis. The success of such a strategymaydepend on several actors, acting in concert. Growth cofactorsmay
be one of these, which call for careful (re)evaluation of their function in normal and in cancermetabolism. This
article is part of a Special Issue entitled: Bioenergetics of Cancer.ergetics of Cancer.
logy, Wageningen University,
, The Netherlands. Tel.: +31
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Nutrition is in many ways related to cancer. It is estimated that 30%
ormore of all cancersmaybe due todietary factors [1]. The view that the
general nutritional status changes cancer risk is strongly supported by
association of obesity with increased risk of colon cancer [2], breast
cancer [3] andmanyother types of cancers [4]. Inmany cases changes in
hormone homeostasis are implicated as the mediating factor. As a
consequence, life style interventions targeting obesity have been
proposed as a means to reduce cancer risk [5]. Cancer risk can also,
beneﬁcially or adversely, be modulated by speciﬁc nutrients. Often this
relation is complex. For example, two large human clinical intervention
studies, the ATBC and the CARET study, have shown an increase in lung
cancer risk and mortality upon high dose supplementation with beta-
carotene of smokers, but no such effect was seen in non-smokers [6,7].
Later also an increased colon cancer risk was reported [8]. On the other
hand, two other large trials, the PHS study and the Linxian study, withmainly (but not only) non-smokers, showed no increased cancer risk
[9,10]. Furthermore, many indications exist that high natural intake of
beta-carotene is associated with a cancer protective effect [11–13]. The
mechanisms underlying the increased cancer risk upon high dose beta-
carotene supplementation in smokers are still not known, but most
likely result from a combination of a high dose supplementation, a long
duration of continuous supplementation and an inﬂammatory condi-
tion that is characteristic for the at risk groups [14]. Many aspects of the
relation between nutrition (and nutrients) and different types of cancer
are excellently reviewed in the secondWRCF/AIR expert report [15].2. Reprogramming of energy metabolism
While it is clear that an association exist between nutritional
status, nutrition and nutrients and cancer, much less is known about
the speciﬁc mechanisms involved, in particular where mitochondria
are concerned. Cancer cells are characterized by unrestricted growth,
which is facilitated by altered mitochondrial function in two different
manners;with respect to apoptosis surveillance andmetabolism. First,
cancer cells are mutated cells. Mitochondria have an important role in
surveying the cell condition and to initiate apoptosis to eliminate
mutated and potential deleterious cells [16], but apparently this
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dria for induction of apoptosis is a valid anti-cancer strategy [17–19],
for which bioactive food components have been suggested [20].
Second, as described already in the 1920s by Otto Warburg, cancer
cells show a shift in energy production from mitochondrial oxidative
phosphorylation (OXPHOS) to cytosolic glycolysis [21]. This so-called
‘aerobic glycolysis’, in which glucose is converted to pyruvate and
lactate in the presence of oxygen, is a major characteristic of most
tumor cells, including colon tumors. Aerobic glycolysis not only
provides the cell with ATP from the readily available substrate glucose,
but the rapid glycolytic ﬂux can also provide the cells with the
necessary substrates, intermediates for lipid, amino acid and DNA
synthesis, that are needed for growth in particular, NADPH, ribose,
acetylCoA and glucose-derived non-essential amino acids. In addition
to an altered use of glucose, cancer cells make energetically inefﬁcient
use of glutamine to supply the nitrogen for the synthesis of nucleotides
and non-essential amino acids, to facilitate import of essential amino
acids and to drive the TCA cycle and support NADPH production.Many
aspects of altered substrate use are described in detail in [22]. The
alteredmetabolic phenotype usually does not result frommutations in
speciﬁc metabolic genes, but rather is the result from mutations in
metabolic regulators. For example, p53 and LKB1, which help cells to
adapt to their glucose and glutamine supply, are often mutated in
cancer cells. The role of p53 and LKB1 in cancer cell metabolism is
described in detail in recent reviews: [23] and [24], respectively. Other
regulators that have an important role in the altered cancer cell
metabolism are phosphatidylinositol-3-kinase (PI3K), Akt, AMP-
kinase (AMPK), mammalian target of rapamycin (mTOR) and, likely,
sirtuins. PI3K/Akt signaling mediates nutrient uptake by activating
hypoxia inducible factor (HIF-1) and c-Myc. Both increase the
expression of glycolytic enzymes and glucose transporters. HIF-1
further diverts pyruvate from the TCA cycle, by activation of PDK1
resulting in inhibition of pyruvate dehydrogenase [25,26], and c-Myc
facilitates glutamate uptake and metabolism [27]. Both HIF-1 and c-
Myc are over-expressed in tumor cells. Together, the metabolic
changes take care of supply of NADPH and acetylCoA, in addition to
ATP, as building blocks for the synthesis ofmacromolecules and satisfy
the need of tumor cells to grow (Fig. 1). Glycolyticmetabolism and the
associated metabolic reprogramming not only support rapid growth,
although at the expense of other cells, but they also make the cancer
cell less dependent of oxygen availability and generates a favorable
(acidic) micro-environment. More detailed descriptions of the altered
cancer cell metabolism, from different perspectives, can be found in
recent reviews [28–34]. Inhibition of glycolysis may have therapeutic
implications in cancer treatment as a strategy to kill cancer cells
[17,35–38]. Such a strategy may also make use of bioactive food
components [39]. It is conceivable that such a strategy may only work
if many actors operate in concert to attain the goal of metabolic
reprogramming. It is therefore important to consider, as reviewed
here, the various roles that bioactive food components, including
micronutrients,may have. One class of bioactive food components that
affect energy metabolism and may have anti-cancer effects are
polyphenols. Indeed, dietary quercetin, a polyphenol present in
apples, onions, tea and wine, that affects energy metabolism [40],
was able to inhibit azoxymethane induced colon carcinogenesis in rats
[41]. This was accompanied with lower expression of glycolytic
enzymes, suggestive of inhibition of glycolytic metabolism [42]. It
should be noted that quercetin is fully gluceronidated in intestinal
cells upon entry in the body, a process that changes is bioactivity [43],
which makes it questionable that the many potential anti-cancer
effects observed in vitro are of relevance in vivo. Another polyphenol
with anti-cancer potential is resveratrol. Resveratrol is well known as
a compound that is present in red wine and is suggested to be
responsible for the ‘French paradox’ [44]. Dietary resveratrol was
shown to beneﬁcially affect energy metabolism of mice fed a high fat
diet. Addition of resveratrol to a high fat diet resulted in reducedweight, increased oxygen consumption, increased mitochondrial
density in muscle and increased physical endurance [45,46]. Recently,
topical administration of resveratrol was shown to protect against
7,12-dimethyl-benz(a)anthracene inducedmouse skin tumor genesis,
by up-regulation of mitochondria mediated apoptosis, involving PI3K/
Akt signaling [47]. Resveratrol is also implicated in other cancer
protective effects, involving variousmechanisms [48,49]. On the other
hand, a cancer stimulatory effect of resveratrol has also been reported
[50]. It should be noted that food bioactives which affect energy
metabolism may work as anti-cancer agents using mechanisms
distinct from their effect on energy metabolism. One example is the
polyphenol epigallocatechingallate (EgCG), the dominant polyphenol
present in green tea. EgCG [51], as well as green tea extracts [52], has
been shown to possess weight lowering effects in rodents and
humans. Oral intake of green tea polyphenols prevents photocarcino-
genesis in the skin ofmice, but themechanismsmost likely involve the
up-regulation of nucleotide excision repair genes [53], rather than
altering energy metabolism. Another potential mechanism of anti-
tumor action of EgCG is through its binding to the laminin receptor
[54], which is over-expressed inmany cancers cells [55]. Indeed, over-
expression of the laminin receptor sensitizes cancer cells to EgCG [56].
Recently, it was shown that vitamin A derived all-trans retinoic acid
enhances the anti-tumor effect of EGCG in an retinoic acid receptor
(RAR)-alpha dependent manner [57]. Polyphenols are anti-oxidants.
The current view is that these and most other dietary anti-oxidant
compounds exhibit their functional effects through speciﬁc cellular
mechanisms, rather than though general, direct anti-oxidants effects
[58], possibly except in the intestinal lumen.
3. Oxygen, an essential growth substrate
Glycolytic metabolism and the associated metabolic reprogram-
ming make the cancer cell less dependent on oxygen [30]. This was
beautifully supported by a recent study of Chen et al. [59]. These
authors identiﬁed the loss of a mitochondrial ribosomal protein as one
of the factors underlying accelerated pancreatic tumor growth in vivo.
This mutation decreased mitochondrial function, increased glycolysis
and increased tumor growth in vivo, where oxygen availability is
limited, but not in vitro, with an abundant presence of oxygen. They
showed that knock down of cytochrome c oxidase, which limits the
need for oxygen, had a similar effect, while the reverse, a need for
oxygen and reduced tumor growth in vivo, was seen with over-
expression of the uncoupling protein UCP-1. In agreement, one of the
principal mechanisms underlying the metabolic shift is the activation
of HIF-1 [60], a transcription factor that activates the conversion of
glucose to lactate [61–63] and facilitates adaptation ofmitochondria to
hypoxia [64,65]. Among others, HIF-1 up-regulates hexokinase (HK)
and lactate dehydrogenase A (LDHA), twometabolic enzymes that are
considered to be of functional relevance in ‘aerobic glycolysis’.
Inhibition of LDHA indeed increases mitochondrial reactive oxygen
production, reduces ATP production and limits cancer progression
[66,67]. HK is of importance not only as a rate limiting factor in
glycolysis, but also because of its role in resistance to apoptosis. HK has
been shown to associate more tightly to the voltage dependent anion
channel (VDAC) in tumors [68], governed by Akt [69–71], which may
result in increased resistance of mitochondrial membrane transition
[72], a crucial factor in mitochondrial mediated apoptosis. Indeed, it
was shown that inhibition of glycolysis sensitizes tumor cells to
apoptosis in an Akt dependent manner [73]. HIF-1 levels increase by
hypoxia through inhibition of its degradation (reviewed in: [74]).
However, under conditions of chronic hypoxia, HIF-1 levels decrease
[75], which is thought to underlie the necrosis that is observed in the
center of solid tumors [76]. Most of the hypoxic regions of tumors are
exposed to ﬂuctuating oxygen levels [77], which stabilize HIF-1 (for
details:[78]). This also accommodates the angiogenesis promoting role
of HIF-1, which is needed to supply nutrients as well as oxygen to
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Fig. 1. Metabolic reprogramming of cancer cells. Cancer cells are metabolically reprogrammed towards ‘aerobic’ glycolyis. Glucose is converted into pyruvate and then to lactate,
which renders 2 ATP molecules of ATP per molecule of glucose. This is in contrast to normal cells where pyruvate enters the mitochondria and is oxidized to CO2, which is far more
energy efﬁcient and renders 32 molecules of ATP per molecule of glucose. Cancer cells compensate for the loss in energetic efﬁciency by using the high capacity of glycolysis, at the
expense of the organism. The advantage to the cancer cell is that it renders the cells less dependent on oxygen and less sensitive to apoptotic surveillance, by various mechanisms
including the association of hexokinase to voltage dependent anion channel (VDAC). A truncated tricitric acid (TCA) cycle functions to deliver the necessary building blocks for cell
growth; e.g. citrate is transported to the matrix where it is converted in oxaloacetate and acetylCoA. Inhibition of hexokinase as well as lactate dehydrogenase contributes to reversal
of the metabolic reprogramming of cancer cells, and both enzymes thus have an essential role in ‘aerobic’ glycolysis. Glutamine metabolism is also altered to facilitate the supply
building blocks for protein, nucleotide and lipid synthesis. Indicated is the production of acetylCoA and NADPH for lipid synthesis. The transcription factors hypoxia inducible factor
(HIF-1) and c-Myc have an important role in these changes. This ﬁgure presents a simpliﬁed version of the altered metabolism of cancers cells, which also involves other regulators
and metabolic switches, such as p53, PI3K/Akt/mTOR, LKB1/AMPK, and others, possibly including sirtuins.
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tumor cells may use lactate produced by themore hypoxic tumor cells
[31]. Although cancer cells have a glycolytic metabolism, oxidative
metabolism, including lipid oxidation, is usually still functioning to
contribute to ATP production [22]. However, the limited amount of
oxygen that is available requires a reduced pyruvate inﬂux into
mitochondria to prevent the production of excess reactive oxygen
species at complex III of the respiratory chain. Reduction of ROS is
further supported increased expression of UCP-2, most likely induced
by the higher ROS levels in tumor cells, and possibly also by increased
lipid turnover. UCP-2 may have a role in apoptosis resistance by
preventing detrimental amounts of ROS (reviewed in: [79]).
4. B- and A-vitamins and mitochondria
For their functioning, mitochondria need energy substrates, glucose
and oxygen, but also cofactors (non-protein compounds needed for
enzyme activity) to perform essential biochemical tasks. Deﬁciencies in
these cofactors are associated with cancer, but generally this does not
result from their role in energy metabolism. Rather this is due to speciﬁc
metabolic alterations, such as the formation of toxic metabolites, alteredmechanisms that protect against reactive oxygen species, and so on.
Among the essential cofactors facilitating energy metabolism are B-
vitamins and A-vitamins. This is brieﬂy described later, focusing on the
role of these vitamins inmitochondrial energymetabolismand indicating
how deﬁciency or excess may result in cancer. Additional information on
the role of B-vitamins inmitochondrial function can be found in extensive
reviews by Depeint et al. [80,81]. Thiamin pyrophosphate, the coenzyme
form of thiamin (vitamin B1), is essential for functioning of the
mitochondrial enzymes pyruvate dehydrogenase, alpha-ketoglutarate
dehydrogenase, branched chain ketoacid dehydrogenases as well as for
transketolase and thus has a central role in energy metabolism. Indeed,
30%of cellular thiamin is estimated to be located inmitochondria (30 μM)
[82] and thiamin deﬁciency results in increased plasma levels of pyruvate
and lactate [83]. Thiamin deﬁciency in rats is associated with an increase
in aberrant crypt foci, an indication of an increase in colon cancer risk,
possibly by increasing genotoxic alpha-oxoaldehydes [84]. Thiamine
pyrophosphate is a cofactor in the rate limiting stepof alpha-ketoglutarate
(oxo-glutarate) dehydrogenase, an enzyme at the crossroads of energy
metabolism, nitrogen assimilation and ROS signaling [85], with a possible
role in modulation of the activity of HIF-1 [86], all aspects that are
deregulated in tumor cells. Riboﬂavin (vitamin B2) is a precursor of ﬂavin
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provides essential prosthetic groups in ﬂavoenzymes. Flavoenzymes
function inmanymetabolic processes, including anti-oxidantmetabolism
(e.g. glutathione reductase [87]), lipid metabolism (e.g. acyl CoA
reductases [88]) and energy metabolism (heme/cytochrome synthesis
[89]). Decreased FAD levels affect folate metabolism by inhibition of
methylene tetrahydrofolate reductase and may thus increase cancer risk
[81]. Flavin is also a coenzymeof the histone lysine speciﬁc demethylase 1
(LSD1), with an important role in tumor genesis [90,91]. Niacin (vitamin
B3) covers two vitaminers, nicotinamide and nicotinic acid, and both are
precursors to NAD(+) and NADP(+) and thus involved in numerous
enzymatic reactions. All energy producing processes, glycolysis as well as
oxidative energy metabolism, depend on enzymes needing this coen-
zyme. Niacin deﬁciency can lead to impaired DNA repair and thus
predisposes to cancer, since NAD(+) is required for poly(ADP)ribose
mediated protection against DNA damage [92]. It should be noted that
niacin deﬁciency is rare in diets with adequate tryptophan, a precursor of
nicotinic acid. Of particular relevance to energy metabolism is the
discovery of sirtuins (SIRT1–7), a family of NAD(+) dependent
deacetylases that may serve as sensors for NAD(+)/NADH in cells and
mitochondria [93–95]. SIRT1 is associated with increased life span in
many organisms [96] and, together with AMP-kinase is one of the
gatekeepers of PGC1-alpha, the master regulator of mitochondrial
biogenesis [97]. Three sirtuins, SIRT3, SIRT4 and SIRT5, are located in
mitochondria [98]. SIRT3 is located in the mitochondrial matrix and was
recently shown to have an important role in the regulation of
mitochondrial fatty acid oxidation [99]. Furthermore, SIRT3 was shown
to function as a tumor suppressor by enhancing the expression of
mitochondrial MnSOD. Loss of SIRT3 leads to increased mitochondrial
ROS, which can enhance cellular transformation and tumor growth [100].
Cytochrome c was identiﬁed as a target of SIRT5 deacetylase function,
providing SIRT5 with a direct role in the regulation of energy production
[101]. Unlikemost other sirtuins, SIRT4 has no deacetylase function, but is
an ADP-ribose transferase with a function in insulin secretion [102].
Pantothenic acid (vitamin B5) is the precursor of coenzyme A (CoA) and
as such is involved in 4% of all enzymatic reactions, including heme
synthesis, cellular, mitochondrial and peroxisomal lipid metabolism, the
citric acid cycleandmitochondrial leucinemetabolism.Panthotenic acid is
present in two cellular pools, as CoA and as acyl carrier proteins, with CoA
being predominantly present in mitochondria (2.2 mM), but also in
peroxisomes (20–140 μM) and in the cytoplasm (less than 15 μM) [103].
Pantothenic acid is shown to protect against reactive oxygen species and
may thus protect against cancer [104]. Pryridoxal/pyridoxamine phos-
phate are the coenzyme form of vitamin B6 (pyridoxine), which is
involved in aminotransferase reactions and is essential for the ureacyle,
the malate aspartate shuttle and in linking amino acid metabolism to
energy production [81]. Vitamin B6 is also intimately involved in one
carbonmetabolism, as are vitaminsB9 andB12.One carbonmetabolism is
essential for protein and DNA methylation and the synthesis of
nucleotides and links these vitamins to cancer. Biotin (vitamin B7) plays
a role in lipid metabolism, with 4 of the 5 biotin dependent carboxylases
being located in mitochondria. Biotin also has a role in gene regulation
through histone modiﬁcation [105]. Histone biotinylation by carboxylase
synthase is sensitive to biotin levels and, among others, has an important
role in the cellular response to double strand DNA breaks [106]. Biotin
deﬁciency can result in heme deﬁciency and because of this, biotin-
deﬁcient cells may selectively loose mitochondrial complex IV [107].
Folate (vitamin B9), which is further discussed later, has no function in
mitochondrial energy metabolism, but has a central role in one carbon
metabolism [81,108]. Cobalamin (vitamin B12) also has an essential role
in one carbonmetabolism [109], and as such, like folate, is associatedwith
(colon) cancer risk. In the formof 5-deoxyadenosylcobalamin (coenzyme
B12), vitamin B12 is required as prosthetic group in methylmalonylCoA
mutase for the synthesis of succinyl-CoA and as such plays an important
role in the TCA cycle and energy metabolism [81,110]. Rapid growing
tumor cells require higher amounts of vitamin B12, and bioconjugation tovitamin B12 is used to deliver anti-tumor agents to tumor cells [110].
Beta-carotene (pro-vitamin A) and its metabolites, retinol (vitamin A),
retinaldehyde and retinoic acid, most likely affect mitochondria and
energy metabolism through effects of different retinoic acid derivatives
via RAR or the retinoic X receptor (RXR), the latter an obligatory
heterodimeric partner of many nuclear receptors involved in transcrip-
tional regulation of energy metabolism [111,112]. Recently, it was found
that retinol is an essential cofactor of mitochondria located PKC-delta,
which regulates the pyruvate dehydrogenase complex. Retinol can thus
enhance energy ﬂux into the citric acid cycle [113]. This provides the ﬁrst
evidence of a fundamental role of retinol in (regulation of) energy
homeostasis. As described previously, beta-carotene supplementation is
associatedwith increased lung cancer risk in at risk individuals through a
still unresolved mechanism. Vitamin A derivatives play a crucial role in
embryonic development, tissue homeostasis, lipid metabolism, cellular
differentiation and proliferation and as such are also linked to cancer
development as well as protection [114].
5. Folic acid
While excess or deﬁciency of cofactors may be associated cancer
initiation, cofactors may also play a role in tumor progression. Rapid
growth of cells not only requires energy substrates, but also sufﬁcient
amounts of essential cofactors, such as folate or vitamin B12. Folate is a
water-soluble B-vitamin (vitamin B9) that naturally occurs in foods,
such as green leafy vegetables, beans, peas and many other types of
vegetables and fruits. Natural folates are pteroylglutamate compounds
that are conjugated to a polyglutamyl chain of different length,
depending on the type of food. This polyglutamyl chain is removed by
the intestinal folate conjugase enzyme before folate-monoglutamate is
taken up by the intestine. If food folates are not in the 5-methyl-
tetrahydrofolate (MTHF) form already, they will be converted to this
form in intestinal mucosa cells [115]. Folic acid, the synthetic form of
folate, is a monoglutamate (pteroylglutamic acid, PGA). This form does
not require cleavage by the intestinal folate conjugase enzyme before
uptake. Folic acid is used for fortiﬁcation of grain products and is present
in vitamin supplements because it is chemically more stable and is
supposedly better bioavailable than natural folates [116]. For physio-
logical activity, folic acid needs to be reduced by the enzyme
dihydrofolate reductase to dihydro- and tetrahydrofolate (DHF and
THF). This occurs within intestinal mucosal cells and MTHF is released
into the plasma [115]. The function of folate is strongly relate to cell
growth, since it has an essential role in the generation of S-
adenosylmethionine, which is required for methylation of DNA and
other substrates, for the synthesis of purines andpyrimidines and for the
metabolism of several amino acids [117–119]. 30–50% of cellular folate
is located in mitochondria, which constitutes a separate pool that does
not equilibrate with the cytosolic folate pool [120–123]. One carbon
metabolism in mitochondria is relatively poorly understood. Many of
the same enzymes are present in mitochondria as in cytoplasm, but the
reactions are more oxidative and use different reducing equivalents
[121,124]. In mitochondria, reduced folates are required for synthesis of
formyl-methionyl t-RNA, and are thus required for initiation of
mitochondrial protein synthesis. Mitochondrial one carbonmetabolism
supplies folate for cytoplasmic one carbon metabolism and generates
glycine. Serine/glycine cycling is thought to occur primarily in
mitochondria, while its role in purine and methionine synthesis occurs
mainly in the cytoplasm. Folate is thus essential for normal cell growth
and cancer prevention, while, on the other hand, it is an essential
cofactor permitting the rapid growth of established cancer cells. Indeed,
animal intervention studies of Song et al. [125,126], using genetically
predisposed murine models of intestinal tumor genesis, support the
dualmodularly role of folate in carcinogenesis. These authors found that
folic acid supplementation suppressed intestinal tumor development in
normal healthy epithelial tissues of Apc+/− and Apc+/−Msh−/−
mice, whereas folate deﬁciency predisposed the animals to neoplastic
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established, PGA supplementationhadapromotingeffect anddeﬁciency
inhibited progression into tumors. This has been supported by later
studies in different models [127] and resulted in a debate on the
potential risk of cereal fortiﬁcation for people with pre-existing
neoplastic lesions [128]. The inhibitory effect of folate deﬁciency in
tissues with rapidly replicating cells shows that sufﬁcient amounts of
folate are essential for tumor growth under physiological relevant
conditions.
6. Is cancer cell growth and glycolytic metabolism interdependent?
When cells turn into tumor cells, they become selﬁsh. Their
metabolism is reprogrammed towards aerobic glycolysis, with a rapid
glycolytic ﬂux supporting rapid growth at the expense of the whole
organism. This diminishes the need for oxygen, relaxes metabolic
control and requires energy substrates (e.g. glucose), but it also
requires essential cofactors needed for growth. While metabolic
reprogramming is well established, many aspects of associated
regulatory alterations and metabolic interdependencies are still not
fully understood. For example, will energy metabolism be altered
under conditions of limiting cofactor availability, or is it a ﬁxed tumor
cell characteristic? Later, as an example, we examine this for folic acid,
a vitamin with no direct role in energy metabolic pathways. While
rapid cancer cell growth is associated with glycolytic metabolism, we
question whether the reverse is also true; whether growth restriction
by limitation of an essential cofactor, such as folic acid, will result in
reduced aerobic glycolysis (and increased oxidative metabolism). We
examine this using the highly glycolytic HT-29 human colon cancer
cell line [129] as an in vitro model.
7. Low folate retards the growth rate of HT-29 cells and alters
its metabolism
HT-29 cells are rapidly growing tumor cells. HT-29 cells cultured in
10 ng/ml PGA, grow signiﬁcantly slower (approximately 2.7 fold,
p=0.0008) compared to HT-29 cells cultured in 100 ng/ml PGA
(Fig. 2A). Intracellular folate levels are lower at 10 ng/ml (p=0.008 for
MTHF and p=0.018 for THF) (Fig. 2B). Since increase of PGA above
100 ng/ml, up to levels that are present in standard culturemedia, did not
result in increased intracellular folate levels (data not shown), nor in
increasedgrowthrates (datanot shown), it canbeconcluded that cofactor
limitation inhibits the growth rate of HT-29 human colon cancer cells.We
then hypothesized that lower growth would result in a decreased
glycolytic metabolism and hence a lower amount of lactate in the culture
medium, relative to the amount of cellular protein as a measure for cell
mass, which was found (p=0.045) (Fig. 2C). To assess whether this was
indeed accompanied by increased respiration, the mitochondrial respira-
tory capacity was analyzed in a standardized experimental regime.
Strikingly, we observed that the routine respiration of HT-29 cells with
lowintracellular folate levels culturedat10 ng/mlwas signiﬁcantlyhigher
compared to culturing at 100 ng/ml folic acid (26.8+/−5.8 vs 17.9+/−
2.6 (expressed as pmol O2/s/1×106 cells+/−SD); n=5, p=0.0.014).
Carbonylcyanidep-triﬂuoromethoxyphenylhydrazone (FCCP) stimulated
respiration, which reﬂects the maximum respiratory capacity of
uncoupled mitochondria in intact cells was also signiﬁcantly higher in
theHT-29cells cultured in10 ng/ml folic acid (87.5+/−16.3vs51.5+/−
4.9 pmolO2/s/1×106 cells+/−SD;n=5, p=0.0015, Fig. 2D). The extent
of respiration inhibition by both oligomycin (inhibits ATP synthase,
so respiration due to leak is measured) and rotenone (inhibits
complex I, so mainly respiration via complex II is measured) was not
statistically different under both conditions (10.9+/−2.1 and 6.9+/−
1.3 vs 12.1+/−0.8 and 6.9+/−1.5 pmol O2/s/1×106 cells; n=5,
p=0.28 and p=0.7, respectively). The respiratory control ratios are
shown inFig. 2E. Respiratory control ratio (RCR)values greater than10are
indicative of well-coupled mitochondria, lower values are indicative of“loose coupling” of the processes of substrate oxidation andATP synthesis
[130]. The RCR are all lower than 10, but HT-29 human colon cancer cells
cultured in 10 ng/ml folic acid have signiﬁcantly (8.1+/−0.6 vs 4.3+/−
0.4; n=5, pb0.0001, Fig. 2E) the highest value. Also the phosphorylation
respiratory control ratio (RCRp) values were signiﬁcantly different.
(0.18+/−0.04 vs 0.11+/−0.05; n=5, p=0.04). There was no
signiﬁcant difference in the uncoupling control ratio (UCR) (3.3+/−0.4
vs 2.9+/−0.4; n=5, p=0.8). Blue native gels established intactness of
all OXPHOS complexes (Fig. 2F). Together this provides evidence that the
lower growth rate induced by limitation of a cofactor that is required for
growth, but not for energymetabolism, results in a shift fromglycolytic to
oxidative metabolism. This strongly suggests a reciprocal relationship
between the type of metabolism and the growth of cancer cells. Growth
cofactor limitation resulting in a shift to oxidative metabolismmay result
in enhanced sensitivity of the cell to apoptosis and/or in an enhanced
oxygen requirement. This is especially attractive since cancer cells have a
higher requirement for cofactors than normal cells.
8. Will nutritional stimulation of mitochondrial biogenesis
counteract glycolytic metabolism in cancer cells?
As mentioned previously, targeting glycolytic metabolism may be
an effective strategy in the cancer therapy. Thismay be done in several
manners, including inhibition of enzymes involved in glucose or
lactate metabolism [67]. Indeed, inhibition of glucose metabolism by
2-deoxyglucose not only inhibited the growth of human mammary
tumorMCF-7 cells in vitro. Feeding of 2-deoxyglucose also delayed the
appearance of mammary tumors in rats [35]. Metabolic normalization
of cancer cells and concomitant inhibition of carcinogenesis may
potentially also be attained by induction of mitochondrial biogenesis.
Mitochondrial biogenesis is mediated by the transcriptional coacti-
vator peroxisome proliferator activated receptor (PPAR)-gamma
coactivator-1alpha (PGC-1alpha) [131–134]. Indeed it has been
suggested that PGC1 activation may be effective in cancer therapy
[135]. In mitochondrial biogenesis, PGC-1alpha associates with
nuclear respiratory factor 1 (NRF-1), Estrogen Related Receptor
alpha (ERR-alpha) [136] and also the PPAR-gamma-RXR dimer.
Further, it induces transcription of NRF-2 and is a cofactor for the
mitochondrial transcription factor A (Tfam) [137]. Two PGC-1alpha
related co-activators have been cloned, PGC-1beta and PGC-1-related
coactivator (PRC), which display partially similar functions, including
NRF-1 [138–141] and ERR-alpha activation [141,142]. PGC-1alpha
activity can be increased by transcriptional activation as well as by de-
acetylation, mediated by SIRT1 [132,143,144], while it can be
inhibited by acetyltransferase GCN5. Indeed its acetylation state is
tightly correlated with its activity [145]. A number of polyphenols are
able to activate SIRT1 [43,146], including resveratrol. In particular,
dietary resveratrol was shown to be able to deacetylate PGC1-alpha,
induce mitochondrial biogenesis and increase metabolic ﬁtness
[45,46]. This was accompanied by increased expression of ERR-
alpha, NRF-1 and Tfam [46]. At this moment it is not clear to which
extent this mechanism contributes to the many reported anti- (or
even pro-) cancer effects of resveratrol [48–50]. Also the marine
omega-3 fatty acids docosahexanoic acid (DHA) and eicosapentanoic
acid (EPA) are able to increase expression of PGC-1alpha and induce
mitochondrial biogenesis [147,148]. Since DHA and EPA have been
implicated in various anti-cancer effects [149,150], it is tempting to
speculate that induction of mitochondrial biogenesis underlies these
effects. However, other mechanisms are strongly implicated, in
particular the induction of apoptosis [151], but also inhibition of
angiogenesis [152], inhibition of inﬂammation [153]. The anti-
inﬂammatory and immuno-regulatory effects are thought to be
largely mediated by resolvins and protectins, speciﬁc metabolic
products derived from DHA and EPA [154,155]. Furthermore, DHA
and EPA are able to activate AMP-kinase (AMPK) [147,156] leading to
activation of fatty acid metabolism. AMPK is a central regulator of the
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Fig. 2. Effects of folate limitation on growth and metabolism of HT-29 cells. HT-29 human colon cancer cells were cultured in 10 ng/ml PGA (10 PGA) or 100 ng/ml PGA (100 PGA,
Control) for 3–3.5 weeks (after habituation at 25 ng/ml PGA) at the start of the analyses. Panel A) For growth determination the cells were re-plated in 75 cm2 cell culture ﬂasks and
the number of cells were counted after 1 and 3 days. Results represent the means+/−SD of 3 independent replicate determinations. Student's t-test gave a signiﬁcant difference in
the number of cells between the groups at day 3 (p=0.0008). Panel B) Intracellular tetrahydrofolate (THF) and 5-methyl-tetrahydrofolate (MTHF) levels (ng per mg protein).
Results represent the means+/−SD of duplicate determinations of 2 independent experiments. Student's t-test gave a signiﬁcant differences for both THF (p=0.018) and MTHF
(p=0.008). Panel C) Lactate wasmeasured in a 72 hour culture medium. Results represent the means+/−SD of 4 replicate determinations of 3 independent experiments. Student's
t-test gave a signiﬁcant difference between the groups (p=0.045). Panel D) FCCP uncoupled respiration. Results represent the means+/−SD of 5 independent duplicate
determinations. Student's t-test gave a signiﬁcant difference between the groups (p=0.0015). Panel E) The respiratory control ratio. Results represent the means+/−SD of 5
independent duplicate determinations. Student's t-test gave a signiﬁcant difference between the groups (pb0.0001). Panel F) Blue native gel electrophoresis of mitochondria
isolated from HT-29 cells. Complexes I–V are indicated and are at the correct position.
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ratio. Physiologically, AMPK can be activated by its upstream kinase
LKB1, a bona ﬁde tumor suppressor. In turn, AMPK can activate PGC-
1alpha and thus activate mitochondrial biogenesis [159]. By phos-
phorylation of phosphofructokinase it can stimulate glycolysis and it
can increase the expression of HK and GLUT4. One of the major
targets, direct, and indirect via tuburin (TSC2), is the mTORC1
complex, a major regulator of cell growth [160,161]. While AMPK
inhibits mTORC1, phosphorylation by Akt stimulates this complex
through TSC2 phosphorylation, which is one of the manners in which
Akt is implicated in the Warburg effect [162]. A role of the energy
sensor AMPK as a tumor suppressor is supported by the observation
that patients on treatment with metformin, an activator of AMPK,
have a lower cancer incidence [163–165]. Of interest, oxidized DHA
derivatives have been shown to be effective ligands of PPAR-gamma[166]. As mentioned, PPAR-gamma associates with PGC-1alpha to
mediate mitochondrial biogenesis, but it is also a target of SIRT1 and
stimulates PGC-1alpha expression. Indeed, it was shown that
thiazolidinediones (TZDs), selective activators of PPAR-gamma,
promote the biogenesis of mitochondria and up-regulate PGC-
1alpha, NRF-1, Tfam and cytochrome c oxidase subunits I and IV
[167]. TZDs have been endowedwith anti-cancer properties. The anti-
cancer effects of TZDs include induction of apoptosis, cell cycle arrest
and apoptosis [168] as well as energy restriction responses [169].
However, recent evidence indicates that these effects are largely
independent of transcriptional activation of PPAR-gamma. TZDs are
also able to activate AMPK [170] and these effects may possibly be
mediated by AMPK. Alternatively, TZDs were shown to reduce
phosphorylation of PPAR-gamma by CDK5 [171]. The resulting altered
metabolic regulation may constitute part of the mechanisms
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component that impinges on AMPK/PGC1alpha signaling, and that
can, in combination with other cofactors, induce mitochondrial
biogenesis, is lipoic acid [172,173]. Whether this explains in the
anti-cancer properties of lipoic acid is not known [174]. Lipoic acid
also has a role in anti-oxidant defence and is a cofactor for
mitochondrial alpha-ketoacid dehydrogenase complexes, functions
which may contribute to in its anti-cancer properties. Other anti-
cancer mechanisms of lipoic acid include the induction of apoptosis,
mediated by the Akt signaling pathway [175], which alsomediates the
effects of lipoic acid on glucose metabolism [176]. It should be noted
that lipoic acid is synthesized in the body, a process that is essential
and cannot be complemented by dietary lipoic acid [177].
Altogether there is no strong evidence for activation of mitochon-
drial biogenesis as a mechanism in the protection against cancer by
bioactive food components. However, at this point it cannot be
concluded that activation of mitochondrial biogenesis could not play a
role in cancer protective effects or even that targeting mitochondrial
biogenesis may not be part of cancer protective strategies involving
bioactive food components.
In targeting speciﬁc metabolic alterations, it should be realized
that many counteracting, homeostatic and partly redundant mechan-
isms exist. For example, activation of mitochondrial biogenesis may
be counteracted by up-regulation of HIF1-alpha, since increased
oxygen consumption may result in hypoxia [178]. Also, cross-talk
exists between different energy sensors in the cell, such as AMPK and
SIRT1 [179] and mTORC1 mediated growth responses are balanced by
Akt and AMPK activities [180]. Furthermore, while both Akt and c-
Myc promote aerobic glycolysis, Akt mediated glycolysis inhibition
sensitizes cells to apoptosis, while c-Myc mediated glycolysis
inhibition sensitizes inhibition of mitochondrial function [73].
9. Conclusion and future perspective
Cancer cells are resistant to apoptosis and show a shift in energy
production from mitochondrial oxidative phosphorylation to cytosolic
glycolysis. The cancer cell uses glucose and the high glycolytic ﬂow for
ATP production and to produce TCA cycle intermediates for lipid, amino
acid and DNA synthesis. This metabolic reprogramming also makes the
cancer cell independent of oxygen availability and generates a favorable
micro-environment. Apoptosis resistance and metabolic programming
are linked in many cancer cells and both processes center on
mitochondria. Clearly, mutated cancer cells escape surveillance and
turn into selﬁsh cells. However, many of the mechanisms that operate
metabolic control still function in cancer cells. Glucose, glycolytic
enzymes, oxygen and growth cofactors are all needed and mitochondria
are a metabolic necessity. This opens the possibility of reversal of
metabolic reprogramming as an attractive strategy to increase suscep-
tibility to surveillance. Nutritional compounds may support this, by
altering metabolism and induction of apoptosis. One example of the
potential of nutritional components is the supportive role of omega-3
fatty acids in cancer therapy [181].Modulation of one pathwaywill, most
likely, inmost cases not be effective.Different bioactive food components,
separate or in support of pharmaceutical interventions, affecting various
aspects of metabolism may, alone or in synergy, provide an important
tool to reverse glycolytic to oxidativemetabolismandenhance sensitivity
to apoptosis. Carefully evaluating the need for metabolic cofactors and
their function inmetabolism, including B- andA-vitamins, should be part
of this strategy.
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